Elicio Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $2.3M | $28.3M |
| Operating income | -$37.7M | -$45.0M | -$35.7M | -$23.7M | -$39.3M |
| Cost of revenue | — | — | — | $0 | $433,000 |
| Cash from operations | -$37.0M | -$37.1M | -$32.7M | -$22.2M | -$52.6M |
| Capital expenditure | $16,000 | $87,000 | $66,000 | $654,000 | $382,000 |
| Free cash flow | -$37.0M | -$37.2M | -$32.8M | -$22.8M | -$53.0M |
| Share repurchases | — | $0 | $150,000 | $0 | — |
| Impairments | $0 | $0 | $0 | $0 | — |
| Total assets | $25.9M | $28.2M | $27.1M | $22.7M | $96.5M |
| Total liabilities | $24.2M | $39.5M | $15.8M | $13.7M | $15.0M |
Shares outstanding 19.1M · Free float 71.4%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.